CN1140992A - 用作抗病毒剂的黄素衍生物 - Google Patents

用作抗病毒剂的黄素衍生物 Download PDF

Info

Publication number
CN1140992A
CN1140992A CN94194350A CN94194350A CN1140992A CN 1140992 A CN1140992 A CN 1140992A CN 94194350 A CN94194350 A CN 94194350A CN 94194350 A CN94194350 A CN 94194350A CN 1140992 A CN1140992 A CN 1140992A
Authority
CN
China
Prior art keywords
flavin
derivatives
riboflavin
hydrogen
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94194350A
Other languages
English (en)
Chinese (zh)
Inventor
O·A·华盛顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RADOPATH Ltd
Original Assignee
RADOPATH Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RADOPATH Ltd filed Critical RADOPATH Ltd
Publication of CN1140992A publication Critical patent/CN1140992A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN94194350A 1993-10-19 1994-10-19 用作抗病毒剂的黄素衍生物 Pending CN1140992A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9321558.0 1993-10-19
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents

Publications (1)

Publication Number Publication Date
CN1140992A true CN1140992A (zh) 1997-01-22

Family

ID=10743784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94194350A Pending CN1140992A (zh) 1993-10-19 1994-10-19 用作抗病毒剂的黄素衍生物

Country Status (26)

Country Link
EP (1) EP0739208A1 (ro)
JP (1) JPH09505804A (ro)
CN (1) CN1140992A (ro)
AP (1) AP620A (ro)
AU (1) AU7943794A (ro)
BG (1) BG100599A (ro)
BR (1) BR9407862A (ro)
CA (2) CA2123825A1 (ro)
CO (1) CO4520283A1 (ro)
CZ (1) CZ113796A3 (ro)
EE (1) EE9600057A (ro)
GB (2) GB9321558D0 (ro)
HR (1) HRP940688A2 (ro)
HU (1) HUT76322A (ro)
IL (1) IL111338A0 (ro)
JO (1) JO1866B1 (ro)
MA (1) MA23356A1 (ro)
MD (1) MD960168A (ro)
NO (1) NO961547L (ro)
OA (1) OA10579A (ro)
PE (1) PE5596A1 (ro)
PL (1) PL314008A1 (ro)
SK (1) SK50696A3 (ro)
UY (1) UY23844A1 (ro)
WO (1) WO1995011028A1 (ro)
ZA (1) ZA948191B (ro)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013142A1 (fr) * 2002-08-02 2004-02-12 The Institute Of Radiation Medicine, Academy Of Miilitary Medical Sciences, People's Liberation Army Derive de riboflavine ainsi que sa fabrication et ses utilisations
US7300372B2 (en) 2002-07-16 2007-11-27 Dayco Europe S.R.L. Con Unico Socio Integrated pulley-torsional damper assembly
CN111565715A (zh) * 2017-10-24 2020-08-21 卢内拉生物技术有限公司 Mitoflavoscin：含靶向黄素的酶通过抑制线粒体呼吸作用消除癌症干细胞(CSCS)
CN114126603A (zh) * 2019-07-09 2022-03-01 帝斯曼知识产权资产管理有限公司 用核黄素或dha降低艾拉弗德的病毒活性

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6933285B2 (en) * 2002-05-10 2005-08-23 The Ohio State University Flavin N-oxides: new anti-cancer agents and pathogen eradication agents
EP2545788A1 (de) * 2011-07-13 2013-01-16 Martin Hulliger Diätisches Mehrkomponentensystem
JP2018131410A (ja) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 カスパーゼ−３阻害剤とその用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
JP2727471B2 (ja) * 1989-09-14 1998-03-11 三井農林株式会社 インフルエンザウィルス感染予防剤
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
WO1993010784A1 (en) * 1991-11-25 1993-06-10 University Of Michigan Therapeutic composition and method for preventing reperfusion injury
JP3073309B2 (ja) * 1992-03-27 2000-08-07 雪印乳業株式会社 シアル酸結合５−デアザフラビン系化合物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300372B2 (en) 2002-07-16 2007-11-27 Dayco Europe S.R.L. Con Unico Socio Integrated pulley-torsional damper assembly
WO2004013142A1 (fr) * 2002-08-02 2004-02-12 The Institute Of Radiation Medicine, Academy Of Miilitary Medical Sciences, People's Liberation Army Derive de riboflavine ainsi que sa fabrication et ses utilisations
CN100413866C (zh) * 2002-08-02 2008-08-27 中国人民解放军军事医学科学院放射医学研究所 核黄素衍生物及其制备方法与应用
CN111565715A (zh) * 2017-10-24 2020-08-21 卢内拉生物技术有限公司 Mitoflavoscin：含靶向黄素的酶通过抑制线粒体呼吸作用消除癌症干细胞(CSCS)
CN114126603A (zh) * 2019-07-09 2022-03-01 帝斯曼知识产权资产管理有限公司 用核黄素或dha降低艾拉弗德的病毒活性

Also Published As

Publication number Publication date
MD960168A (ro) 1998-04-30
HUT76322A (en) 1997-08-28
HU9601006D0 (en) 1996-06-28
NO961547D0 (no) 1996-04-18
EE9600057A (et) 1996-10-15
PE5596A1 (es) 1996-04-18
GB9421099D0 (en) 1994-12-07
IL111338A0 (en) 1994-12-29
EP0739208A1 (en) 1996-10-30
AP620A (en) 1997-10-14
SK50696A3 (en) 1997-01-08
CA2174552A1 (en) 1995-04-27
CO4520283A1 (es) 1997-10-15
BR9407862A (pt) 1997-05-20
GB9321558D0 (en) 1993-12-08
ZA948191B (en) 1995-06-08
CZ113796A3 (en) 1996-11-13
BG100599A (en) 1997-02-28
JO1866B1 (en) 1995-12-27
HRP940688A2 (en) 1997-04-30
NO961547L (no) 1996-06-19
UY23844A1 (es) 1995-03-28
PL314008A1 (en) 1996-08-05
AU7943794A (en) 1995-05-08
JPH09505804A (ja) 1997-06-10
GB2283913A (en) 1995-05-24
AP9400695A0 (en) 1995-01-31
CA2123825A1 (en) 1995-04-20
WO1995011028A1 (en) 1995-04-27
OA10579A (en) 2002-06-19
MA23356A1 (fr) 1995-07-01

Similar Documents

Publication Publication Date Title
CN1147766A (zh) 治疗感染的药物
CN1140992A (zh) 用作抗病毒剂的黄素衍生物
CN1516582A (zh) 抗病毒化合物
Dereuddre-Bosquet et al. MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV162P3 in cynomolgus macaques
CN1622814A (zh) 抗肿瘤活性吲哚并吡咯并咔唑衍生物和其它抗肿瘤药物的联合应用
Van Rompay et al. CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment
CN1805740A (zh) 下调ccr5表达的组合物及其应用方法
CN1072654C (zh) 苯甲酰胺衍生物,含所述衍生物的组合物及它们的用途
US10052327B2 (en) Method for treating liver diseases of various origins
CN109414508A (zh) 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
CN1183964C (zh) 胸腺素α1与拉米夫定组合或者与拉米夫定及泛昔洛韦组合制备治疗乙型肝炎感染的药物组合制剂中的应用
CN1325305A (zh) 以低的副作用施用喜树碱化合物治疗癌症的方法
Pedersen et al. 16α-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression
CN107157978A (zh) 治疗ebv+dlbcl和dlbcl的药物及组合物
CN1940089A (zh) 一种同时快速检测hbv、hcv、hiv、tp和rv的方法
CN114259492A (zh) 硝唑尼特在治疗乙肝中的应用
CN1520818A (zh) 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
JP2023525103A (ja) ウイルス感染の治療のための化合物の使用
US20090169519A1 (en) Medicinal formulation containing a combination of hiv type i and hiv type ii
CN1546533A (zh) 猴头菌硫酸酯蛋白多糖、其制备方法和以该化合物为活性成分的药物组合物
EP1499330B1 (fr) Therapie par l'arsenic de maladies autoimmunes
JPH01149730A (ja) レトロウイルス増殖抑制剤
CN1589143A (zh) 癌症治疗的方法
EP0600915B1 (fr) Composition a base de buis pour le traitement de l'infection par le vih (virus de l'immunodeficience humaine)
CN1218698C (zh) 用于治疗和预防肝纤维化和肝硬化的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication